Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors

Current Opinion in HIV and AIDS

Volumn 4, Issue 2, 2009, Pages 112-117

  Chen, Weizao ^a   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Domain antibody; HIV 1; Human; Monoclonal antibody; Neutralization

Indexed keywords

2F5 MONOCLONAL ANTIBODY; 2G12 MONOCLONAL ANTIBODY; 4E10 MONOCLONAL ANTIBODY; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; B12 MONOCLONAL ANTIBODY; C34 PEPTIDE; CBETA1 MONOCLONAL ANTIBODY; CGP 47 439; CGP 47 439 MONOCLONAL ANTIBODY; EPITOPE; F105 MONOCLONAL ANTIBODY; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IBALIZUMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; KD 247; KD 247 MONOCLONAL ANTIBODY; NM 01; NM01 MONOCLONAL ANTIBODY; PEPTIDE; PRO 140; SCFV M 9 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; X5 MONOCLONAL ANTIBODY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ANTIBODY ENGINEERING; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CROSS REACTION; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LYMPHOID CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; VIRUS ENTRY; VIRUS NEUTRALIZATION; VIRUS REPLICATION; GENETICS; IMMUNOLOGY; SERODIAGNOSIS;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS;

EID: 65549146370     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328322f95e     Document Type: Review

References (45)

1. Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis 2002; 8:833-841. (Pubitemid 34940526)
2. Nagarajan T, Rupprecht CE, Dessain SK, et al. Human monoclonal antibody and vaccine approaches to prevent human rabies. Curr Top Microbiol Immunol 2008; 317:67-101.
3. Klasse PJ, Sattentau QJ. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 2002; 83:2091-2108.
4. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312.
5. Manrique A, Rusert P, Joos B, et al. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 2007; 81:8793-8808. This study performs an in-depth analysis of the emergence of virus mutations conferring resistance to nhmAbs, 2G12, 2F5 and 4E10, in HIV-1-infected individuals.
6. Stiegler G, Armbruster C, Vcelar B, et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS 2002; 16:2019-2025. (Pubitemid 35205265)
7. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75:8340-8347.
8. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9:343-346. (Pubitemid 36362791)
9. Cavacini LA, Samore MH, Gambertoglio J, et al. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses 1998; 14:545-550. (Pubitemid 28196781)
10. Mascola JR, Lewis MG, Stiegler G, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73:4009-4018. (Pubitemid 29189846)
11. Armbruster C, Stiegler GM, Vcelar BA, et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002; 16:227-233. (Pubitemid 34118570)
12. Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622. (Pubitemid 40868301)
13. Emini EA, Schleif WA, Nunberg JH, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992; 355:728-730.
14. Eda Y, Murakami T, Ami Y, et al. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J Virol 2006; 80:5563-5570. (Pubitemid 43752802)
15. Gunthard HF, Gowland PL, Schupbach J, et al. A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120. J Infect Dis 1994; 170:1384-1393. (Pubitemid 24369896)
16. Dezube BJ, Doweiko JP, Proper JA, et al. Monoclonal antibody hNM01 in HIV-infected patients: a phase I study. J Clin Virol 2004; 31:S45-S47.
17. Kuritzkes DR, Jacobson J, Powderly WG, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189:286-291. (Pubitemid 38147253)
18. Jacobson JM, Saag MS, Thompson MA, et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008; 198:1345-1352. This very recent human clinical trail shows that an anticoreceptor CCR5 mAb confers significant antiviral activity in vivo.
19. Chen W, Zhu Z, Feng Y, Dimitrov DS. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci U S A 2008; 105:17121-17126. The first human dAb against HIV-1 identified from a large phage-displayed library exhibits exceptionally potent broadly cross-reactive neutralizing activity by targeting the highly protected sterically restricted regions on gp120. This finding could open an avenue fordeveloping a novel class of potent HIV inhibitors based on humandAbs.
20. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-104. This study provides proof of concept that antibody Fc receptor-mediated effector functions are vital for protection against HIV. (Pubitemid 47373775)
21. Choudhry V, Zhang MY, Dimitrova D, et al. Antibody-based inhibitors of HIV infection. Expert Opin Biol Ther 2006; 6:523-531.
22. Huber M, Olson WC, Trkola A. Antibodies for HIV treatment and prevention: window of opportunity? Curr Top Microbiol Immunol 2008; 317:39-66. A very recent review summarizes the diverse specificities and modes of action of therapeutic antibodies against HIV-1 and discusses the success, challenges and future opportunities of antibodies for therapy of HIV-1 infection.
23. Roben P, Moore JP, Thali M, et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994; 68:4821-4828. (Pubitemid 24226546)
24. Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266:1024-1027. (Pubitemid 24373715)
25. Binley JM, Wrin T, Korber B, et al. Comprehensive cross-clade neutralization analysis of a panel of antihuman immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:13232-13252. (Pubitemid 39507829)
26. Trkola A, Purtscher M, Muster T, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996; 70:1100-1108. (Pubitemid 26029030)
27. Stiegler G, Kunert R, Purtscher M, et al. Apotent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodefi- ciency virus type 1. AIDS Res Hum Retroviruses 2001; 17:1757-1765. (Pubitemid 34114213)
28. Zwick MB, Labrijn AF, Wang M, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75:10892-10905. (Pubitemid 33034579)
29. Mascola JR, Louder MK, VanCott TC, et al. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J Virol 1997; 71:7198-7206.
30. Armbruster C, Stiegler GM, Vcelar BA, et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother 2004; 54:915-920. (Pubitemid 39529987)
31. Huber M, von Wyl V, Ammann CG, et al. Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. J Virol 2008; 82:3834-3842. The authors show that the in-vivo activities of antibodies 2G12, 2F5 and 4E10 are probably due to direct neutralization or Fc receptor-mediated mechanisms, such as phagocytosis and ADCC, or both instead of complement-mediated virolysis, in agreement with a previous study on antibody b12 [20••].
32. Labrijn AF, Poignard P, Raja A, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003; 77:10557-10565. (Pubitemid 37129699)
33. Moulard M, Phogat SK, Shu Y, et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A 2002; 99:6913-6918. (Pubitemid 34526232)
34. Zhang MY, Shu Y, Rudolph D, et al. Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J Mol Biol 2004; 335:209-219. (Pubitemid 37494973)
35. Zhang MY, Shu Y, Sidorov I, Dimitrov DS. Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades. Antiviral Res 2004; 61:161-164. (Pubitemid 38183055)
36. Holt LJ, Herring C, Jespers LS, et al. Domain antibodies: proteins for therapy. Trends Biotechnol 2003; 21:484-490.
37. Chen W, Zhu Z, Feng Y, et al. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol 2008; 382:779-789. This study describes the design and construction of a large high-quality phage-displayed human dAb library, from which many high-affinity dAbs were selected against cancers and viruses, including the first human dAb against HIV-1, m36.
38. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998; 393:705-711. (Pubitemid 28289663)
39. Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393:648-659. (Pubitemid 28289647)
40. Berkower I, Patel C, Ni Y, et al. Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding. Virology 2008; 377:330-338.
41. Huang CC, Tang M, Zhang MY, et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005; 310:1025-1028.
42. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988; 48:7022-7032.
43. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007; 109:170-179. This review discusses the potential of small-size antibody fragments in penetrating human solid tumors.
44. Muller D, Karle A, Meissburger B, et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007; 282:12650-12660. The authors show that fusion to human serum albumin strongly increases the circulation time of antibody fragments, suggesting the potential usefulness of this strategy to improve the pharmacokinetics of small proteins in vivo. (Pubitemid 47100581)
45. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008; 22:315-329. The authors extensively review the impact of PEGylation on biological therapies. The conclusion is that PEGylation of therapeutic proteins, including antibodies, significantly improves the pharmacokinetic behavior of drugs.